Bank Pictet & Cie Europe AG Has $8.39 Million Position in Moderna, Inc. $MRNA

Bank Pictet & Cie Europe AG cut its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 55.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 324,665 shares of the company’s stock after selling 409,021 shares during the period. Bank Pictet & Cie Europe AG owned 0.08% of Moderna worth $8,386,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the company. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in shares of Moderna by 58.4% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 36,600 shares of the company’s stock worth $945,000 after buying an additional 13,500 shares during the period. Legal Advantage Investments Inc. bought a new stake in shares of Moderna during the 3rd quarter worth approximately $1,244,000. 180 Wealth Advisors LLC boosted its holdings in shares of Moderna by 13.9% in the 3rd quarter. 180 Wealth Advisors LLC now owns 27,252 shares of the company’s stock valued at $704,000 after purchasing an additional 3,324 shares in the last quarter. Collar Capital Management LLC boosted its stake in Moderna by 18.5% in the third quarter. Collar Capital Management LLC now owns 38,565 shares of the company’s stock valued at $996,000 after buying an additional 6,034 shares in the last quarter. Finally, CWM LLC grew its holdings in shares of Moderna by 50.1% during the 3rd quarter. CWM LLC now owns 390,333 shares of the company’s stock valued at $10,082,000 after purchasing an additional 130,200 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of recent research reports. Leerink Partners upped their target price on Moderna from $15.00 to $18.00 and gave the stock an “underperform” rating in a report on Friday, November 21st. Piper Sandler restated an “overweight” rating on shares of Moderna in a report on Monday, December 1st. UBS Group restated a “buy” rating on shares of Moderna in a report on Friday, November 21st. Berenberg Bank set a $28.00 target price on Moderna in a research note on Monday, November 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moderna in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $29.21.

Insider Activity

In related news, Director Noubar Afeyan sold 23,853 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the sale, the director owned 3,924 shares in the company, valued at $115,679.52. The trade was a 85.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 10.90% of the company’s stock.

Moderna Stock Down 3.0%

MRNA opened at $29.49 on Friday. The firm has a 50-day moving average price of $27.25 and a 200-day moving average price of $27.47. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $48.92. The company has a market capitalization of $11.52 billion, a price-to-earnings ratio of -3.65 and a beta of 1.17.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $893.29 million. During the same period in the previous year, the company posted $0.03 EPS. The firm’s revenue for the quarter was down 45.4% compared to the same quarter last year. On average, sell-side analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.